Document:

2014 Form 10-K Ex 10.54 (C)

Exhibit 10.54
AMENDMENT NO. 1 TO THE
VWR CORPORATION 2014
EMPLOYEE STOCK PURCHASE PLAN
		
	1.
	Definitions.  Capitalized terms used but not defined in this Amendment shall have the meanings assigned to them in the VWR Corporation 2014 Employee Stock Purchase Plan (the “Plan”).

		
	2.
	Amendment of the Plan.  The Plan is hereby amended as follows effective as of March 1, 2015: 

		
	(a)
	The definition of “Employee” set forth in Section 1.2 of the Plan is hereby deleted in its entirety and replaced with the following:

“Employee” shall mean any full-time or part-time employee of the Company or a Designated Subsidiary who customarily works for the Company or Designated Subsidiary, as the case may be, for a minimum of eighteen (18) hours per week.”
		
	(b)
	Section 2.1 of the Plan is hereby deleted in its entirety and replaced with the following: 

“2.1    Eligibility.  Participation in the Plan is limited to Employees who meet the requirements of this Section 2.1.  Each Employee who, on the start date of an Option Period, will have at least one hundred eighty (180) days of Continuous Service may become a Participant by completing the enrollment procedures prescribed by, or on behalf of, the Committee or the Plan Manager, as revised from time to time.  Employees who are included in a unit of Employees covered by a collective bargaining agreement subject to the National Labor Relations Act, 29 U.S.C. §§ 151-169, shall be eligible to participate in the Plan if such agreement provides that the Employees shall be covered by the Plan or the collective bargaining representatives and the Company or Designated Subsidiary, as applicable, have otherwise agreed to extend coverage under the Plan to such Employees.  No Employee may participate in the Plan if such Employee, immediately after the end of an Option Period, would be deemed for purposes of Section 423(b)(3) of the Code to possess five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any subsidiary.  The Committee may, prior to the commencement of an Option Period, exclude from participation any Employee who, at the time of the commencement of the Option Period, is a highly compensated employee (within the meaning of Section 414(q) of the Code) or is an officer of the Company subject to the reporting requirements of Section 16(a) of the Securities Exchange Act of 1934; provided that such exclusion is applied  in an identical manner to all such highly compensated employees or officers of the Company and each Designated Subsidiary whose employees are Participants under the Plan.”
*     *     *     *     *
IN WITNESS WHEREOF, VWR Corporation has caused this Amendment No. 1 to be duly executed this 27th day of February, 2014.
	
			
	Attest:
	 
	VWR CORPORATION

	 
	 
	 

	/s/ Scott Baker
	 
	By: /s/ George Van Kula

	Scott Baker
	 
	George Van Kula

	Vice President and Assistant General Counsel - Corporate
	 
	Senior Vice President, Human Resources, General Counsel and Secretary2014 Form 10-K Ex 10.56 (C)

Exhibit 10.56
TERMINATION AGREEMENT
This TERMINATION AGREEMENT (this “Agreement”) is entered into as of October 7, 2014 by and among VWR Funding, Inc., a Delaware corporation (“VWR Funding”), Madison Dearborn Partners V-B, L.P., a Delaware limited partnership (“MDP”) and Avista Capital Holdings, L.P., a Delaware limited partnership (“Avista” and, together with VWR Funding and MDP, the “Parties”).  Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Management Agreement (as defined below).
WHEREAS, VWR Corporation, a Delaware corporation (“VWR Corp”), filed a Registration Statement on Form S-1 with the Securities and Exchange Commission on June 24, 2014 under the Securities Act of 1933, as amended, relating to the initial sale to the public in an underwritten public offering of the common stock of VWR Corp (an “IPO”);
WHEREAS, each of the Parties is party to that certain Amended and Restated Management Services Agreement, dated as of August 20, 2007 (the “Management Agreement”); and
WHEREAS, each of the Parties desires to terminate the Management Agreement, subject to certain exceptions, effective upon the consummation of an IPO (the “Effective Time”) on or prior to December 31, 2014.
NOW, THEREFORE, in consideration of the foregoing recitals and the covenants and conditions herein set forth, the Parties agree as follows:
1.    Effectiveness.  This Agreement shall become effective only upon and as of the Effective Time.  Notwithstanding any implication herein to the contrary, this Agreement shall automatically be null and void and shall automatically be of no force and effect, and the Management Agreement shall remain in full force and effect, if an IPO is not consummated on or prior to December 31, 2014.
2.    Termination of the Management Agreement.  At the Effective Time, the Management Agreement shall terminate and be of no further force or effect; provided that the provisions of Paragraph 4 (Reimbursement of Expenses; Independent Contractor), Paragraph 8 (Liability), and Paragraph 9 (Indemnification of Advisors) of the Management Agreement, and the obligation of VWR Funding to pay any fees, costs and expenses incurred by either MDP or Avista in rendering services thereunder and not reimbursed or paid by VWR Funding as of the Effective Time shall survive termination of the Management Agreement.
3.    IPO Expenses.  Without limiting the obligations of VWR Funding under the Management Agreement, in furtherance of the provisions of Paragraph 4 of the Management Agreement and not in duplication thereof, upon the consummation of an IPO, VWR Funding shall promptly reimburse MDP and Avista for all expenses incurred by each in connection with such IPO.
4.    Release.  As of the Effective Time, VWR Funding releases and discharges each of MDP and Avista, their parents, affiliates, and subsidiaries, and their respective officers, directors, employees, agents, successors and assigns from and against each and every right, claim, debt, demand, action, complaint, cause of action, grievance, suit or proceeding of every kind, at law or in equity, whether known or unknown, which VWR Funding has or may have in the future arising out of, resulting from, or in any way relating to the Management Agreement.

5.    General.
(a)    No amendment or waiver of any provision of this Agreement, or consent to any departure by either party from any such provision, shall in any event be effective unless the same shall be in writing and signed by the parties to this Agreement and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.
(b)    This Agreement and the Management Agreement shall constitute the entire agreement between the Parties with respect to the subject matter hereof and thereof, and shall supersede all previous oral and written (and all contemporaneous oral) negotiations, commitments, agreements and understandings relating hereto.
(c)    THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF ILLINOIS APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED THEREIN, AND THE PARTIES TO THIS AGREEMENT HEREBY AGREE TO SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED IN THE STATE OF ILLINOIS IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT. This Agreement shall inure to the benefit of, and be binding upon, VWR Funding, MDP, Avista and their respective successors and assigns.
(d)    EACH PARTY TO THIS AGREEMENT HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (A) ARISING UNDER THIS AGREEMENT OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE.
(e)    This Agreement may be executed in two or more counterparts, and by different parties on separate counterparts, each set of counterparts showing execution by all parties shall be deemed an original, but all of which shall constitute one and the same instrument.
(f)    The waiver by any party of any breach of this Agreement shall not operate as or be construed to be a waiver by such party of any subsequent breach.
[Signature pages follow]

2

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by their duly authorized officers or agents as set forth below.
VWR FUNDING, INC.
	
		
	By:
	/s/ James M. Kalinovich

	Name:
	James M. Kalinovich

	Title:
	Vice President & Corporate Treasurer

MADISON DEARBORN PARTNERS V-B, L.P. 
	
		
	By:
	Madison Dearborn Partners, LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Timothy P. Sullivan

	Name:
	Timothy P. Sullivan

	Title:
	Managing Director

AVISTA CAPITAL HOLDINGS, L.P.
	
		
	By:
	Avista Capital, Inc.

	Its:
	General Partner

	 
	 

	By:
	/s/ Ben Silbert

	Name:
	Ben Silbert

	Title:
	General Counsel

[Signature Page to Termination Agreement]Exhibit 10.1

 

 

CHINA BIOLOGIC PRODUCTS, INC.

DIRECTOR AGREEMENT

 

THIS AGREEMENT (The “Agreement”)
is made on March 4, 2015 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as
the “Company”), and Mr. Min Fang (hereinafter referred to as the “Director”).

 

BACKGROUND

 

The Board of Directors
of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director
perform the duties of a director and the Director desires to be so appointed for such position and to perform the duties required
of such position in accordance with the terms and conditions of this Agreement.

 

AGREEMENT

 

In consideration for
the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged,
the Company and the Director hereby agree as follows:

 

1.DUTIES.
The Company requires that the Director be available to perform the duties of a director customarily related to this function as
may be determined and assigned by the Board of Directors of the Company and as may be required by the Company’s constituent
instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and board committee charters,
each as amended or modified from time to time, and by applicable law, including by the Delaware General Corporation Law (the “DGCL”).
The Director agrees to devote as much time as is necessary to perform completely the duties as the Director of the Company. The
Director will perform such duties described herein in accordance with the general fiduciary duty of directors arising under the
DGCL.

 

2.TERM.
The term of this Agreement shall commence as of the date of the Director’s appointment by the Board of Directors of the Company
and shall continue until the Director’s removal or resignation.

 

3.COMPENSATION. The
Director waives any right to compensation in connection with the services provided hereunder.

 

4.EXPENSES.
The Company will reimburse the Director for pre-approved reasonable business related expenses incurred in good faith in the performance
of the Director’s duties for the Company. Such payments shall be made by the Company upon submission by the Director of a
signed statement itemizing the expenses incurred. Such statement shall be accompanied by sufficient documentary matter to support
the expenditures.

 

5.CONFIDENTIALITY.
The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished,
the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs,
including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets
of the Company (“Confidential Information”). The Director covenants not to, either directly or indirectly, in
any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information.

 

    	 

    	 

    

 

 

6.NON-COMPETE.
During the term of this Agreement (the “Restricted Period”), the Director shall not, directly or indirectly,
(i) in any manner whatsoever engage in any capacity with any business competitive with the Company’s current lines of business
or any business then engaged in by the Company, any of its subsidiaries or any of its affiliates (the “Company's Business”)
for the Director’s own benefit or for the benefit of any person or entity other than the Company or any subsidiary or affiliate;
or (ii) have any interest as owner, sole proprietor, shareholder, partner, lender, director, officer, manager, employee, consultant,
agent or otherwise in any business competitive with the Company's Business; provided, however, that (x) this Clause
6 shall not be deemed to prohibit any investment activities of Warburg Pincus LLC and its affiliated funds and the Director’s
activities in connection therewith, provided further that the Director cannot act as a director in any company engaging in business
similar to or competing with the Company’s Business without the Company’s written consent, and (y) the Director may
hold, directly or indirectly, solely as an investment, not more than two percent (2%) of the outstanding securities of any person
or entity which are listed on any national securities exchange or regularly traded in the over-the-counter market notwithstanding
the fact that such person or entity is engaged in a business competitive with the Company's Business.

 

7.TERMINATION.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination.
Nothing contained herein or omitted herefrom shall prevent the shareholder(s) of the Company from removing the Director with immediate
effect at any time for any reason.

 

8.INDEMNIFICATION.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Delaware,
and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the
Indemnification Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in
the Director’s official capacity and as to action in another capacity while holding such office. The Company and the Director
are executing the Indemnification Agreement in the form attached hereto as Exhibit A.

 

9.EFFECT
OF WAIVER. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.

 

10.NOTICE. Any and
all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature page hereto
or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities and
Exchange Commission and if by fax to +8610 6598 3222.

 

    	2

    	 

    

 

11.GOVERNING
LAW. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the
laws of the State of New York without reference to that state’s conflicts of laws principles.

 

12.ASSIGNMENT.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder
shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the
Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without
the prior written consent of the Company.

 

13.MISCELLANEOUS.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such
invalidity or illegality, the remaining terms and provisions of the this Agreement shall remain in full force and effect in the
same manner as if the invalid or illegal provision had not been contained herein.

 

14.ARTICLE
HEADINGS. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.

 

15.COUNTERPARTS.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument.
Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.

 

16.ENTIRE
AGREEMENT. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect
to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or
warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to
such subject matter.

 

 

[Signature Page Follows]

    	3

    	 

    

IN WITNESS WHEREOF,
the parties hereto have caused this Director Agreement to be duly executed and signed as of the day and year first above written. 

 

 

	 	CHINA
BIOLOGIC PRODUCTS, INC.
	 	 
	 	By: 	/s/ David (Xiaoying) Gao	 
	 	Name:  David (Xiaoying) Gao

                    Title:  Chairman & Chief Executive Officer

	 	                 	 
	 	 	 

  

	 	DIRECTOR
	 	 
	 	By: 	/s/ Min Fang	 
	 	Name:  Min Fang

                    

	 	 	 
	 	Address: 	 
	 	 	 
	 	 	 

 

 

 

    	4

    	 

    

EXHIBIT A

 

Form of Indemnification Agreement

 

(See Attached)

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]